Pfizer Inc and BioNTech SE announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.
source https://www.pharmatutor.org/pharma-news/2020/pfizer-begins-human-trial-of-covid-19-vaccine
No comments:
Post a Comment